Generic Name: Bupropion HCL.

Presentation: Tab 150 mg(film-coated, sustained-release) x 10’s.

Indications & Usage - Aid to smoking cessation treatment.

Dosage & Administration:
Smoquit SR should be commenced at 150mg/day for the first 3 days, followed by a dose increase, for most patients, to the recommended usual dose of 300 mg/day, given as 150mg twice daily.
Recommended Maximum Dose: 300mg/day. Treatment with Smoquit SR should be initiated while the patient is still smoking and target quitting date should be set within the first 2 weeks of treatment, usually within the 2nd week.
Recommended Duration of Treatment for Smoking Cessation: 7-12 weeks, longer treatment should be guided by the relative benefits and risks for individual patients. Bupropion should be discontinued after 7 weeks of treatment if the patient has not made progress towards abstinence from smoking at that time.
Patients with Renal or Hepatic Impairment: Dosages should be modified depending on clinical response and degree of renal or hepatic impairment, but no quantitative recommendations are available.

Overdosage:
There is limited information regarding the effects of an overdose of sustained-release bupropion. The most common symptoms after an overdose of sustained-release bupropion experienced in clinical trials included seizure, blurred vision lightheadedness, lethargy, nausea and visual hallucinations; all patients recovered without sequelae.
Treatment: Ensure an adequate airway, oxygenation and ventilation. Monitor cardiac rhythm and vital signs. EEG monitoring is also recommended for the first 48 hrs post-ingestion.Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Activated charcoal should be administered. Seizure should be treated with IV benzodiazepine and other supportive measures.

Sin Phyu Kyun Co.,Ltd.
No. 100/102, 52nd St,
Pazundaung Tsp,
Yangon, Myanmar.
Tel: 290 055, 293 312
Fax: 095 293 312
E-mail; utasbg@
mptmail.net.mm

Generic Name: Pioglitazone HCL

Presentation: Tab 15 mg x 10’s. 30 mg x 10’s.

Indications & Usage -
Monotherapy as adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus.
For use in combination with a sulfonylurea, metformin or insulin when diet and exercise plus the single agent does not result in adequate glycaemic control in patients with type 2 diabetes.

Dosage & Administration:
The management of antidiabetic therapy should be individualized. Pioglitazone should be taken once daily without regard to meals.

Overdosage:
Limited data are available with regard to overdosage in humans. No clinical symptoms were reported when a male patient took pioglitazone in the dose of 120 mg daily for 4 days and then 180 mg daily for 7 days,In the event of an overdosage, supportive treatment should be initiated as directed by the patient’s clinical status.

Sin Phyu Kyun Co.,Ltd.
No. 100/102, 52nd St,
Pazundaung Tsp,
Yangon, Myanmar.
Tel: 290 055, 293 312
Fax: 095 293 312
E-mail; utasbg@
mptmail.net.mm

Generic Name: Repaglinide.

Presentation: Tab0.25 mg x 10’s. 2 mg x 10’s.4 mgx 10’s.

Indications & Usage -
As an adjunct to diet and exercise to lower the blood glucose levels in patients with type 2 diabetes mellitus (NIDDM) whose hyperglycaemia cannot be controlled satisfactorily by diet and exercise alone. Also indicated for use in combination with metformin to lower blood glucose in patients whose hyperglycaemia cannot be controlled satisfactorily by diet, exercise and either repaglinide or metformin alone.

Dosage & Administration:
There is no fixed-dosage regimen for the management of type 2 diabetes with repaglinide.Short-term duration of repaglinide may be sufficient during periods of transient loss of control in patients who are usually well controlled on diet. Repaglinide doses are usually taken within 15 min of the meal but time may vary from immediately preceding the meal to as long as 30 min before the meal. Starting Dose: For patients not previously treated or whose glycosylated haemoglobin is <8%, the starting dose should be 0.5 mg with each meal. For patients previously treated with blood glucose-lowering drug and whose glycosylated haemoglobin is 8%, the initial dose is 1 or 2 mg with each meal preprandialy.Dose Adjustment: Dosage adjustment sould be determined by blood glucose response, usually fasting blood glucose. The preprandial dose should be doubled up to 4 mg with each meal unitil satisfactory blood glucose response is achieved. At least 1 week should elapse to assess response after each dose adjustment. Recommended Dose Range: 0.5-4 mg taken with meals. Repaglinide may be dosed preprandially 2,3 or 4 times a day in response to changes in the patient’s meal pattem. Maximum Recommended Daily Dose: 16mg. No dosage adjustments are required for the elderly.
Combination Therapy: The starting dose and dose adjustments for repaglinide combination therapy is the same as for repaglinide monotherapy. The dose of each drug should should be carefully adjusted to determine the minimal dose required to achieve the desired pharmacological effect. Appropriate monitoring of fasting plasma glucose and glycosylated haemoglobin measurements should be used to ensure that the patient is not subjected to execessive drug exposure or increased probabillity of secondary drug failure.

Overdosage:
There were few adverse effects other than those associated with the intended effect of lowering blood glucose in the patients who received increasing doses of repaglinide up to 80mg a day for 14days. Hypoglycaemia did not occur when meals were given with these high doses, Hypoglycaemic symptoms without loss of consciouseness or neurologic findings should be treated aggressively with oral glucose and adjustment in drug dosage and/or meal patterns. Severe hypoglycaemic reactions with comais diagnosed or suspected, the patient should be given a rapid IV injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100mg/dL.

Sin Phyu Kyun Co.,Ltd.
No. 100/102, 52nd St,
Pazundaung Tsp,
Yangon, Myanmar.
Tel: 290 055, 293 312
Fax: 095 293 312
E-mail; utasbg@
mptmail.net.mm